Spots Global Cancer Trial Database for metastatic prostate carcinoma

Every month we try and update this database with for metastatic prostate carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer	NCT02522715	Castration-Resi... Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Cabazitaxel Enzalutamide Laboratory Biom... Pharmacological... Prednisone	18 Years -	OHSU Knight Cancer Institute
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer	NCT04592237	Aggressive Vari... Castration-Resi... Metastatic Pros... Metastatic Pros... Metastatic Pros... Stage IV Prosta...	Cabazitaxel Carboplatin Cetrelimab Niraparib	18 Years -	M.D. Anderson Cancer Center
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer	NCT03805594	Castration Leve... Castration-Resi... Metastatic Pros... Prostate Adenoc... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Lutetium Lu 177... Pembrolizumab	18 Years -	University of California, San Francisco
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer	NCT00748358	Prostatic Neopl... Neoplasms, Horm... Tumor Markers, ... Survival Rate Disease-Free Su...	sunitinib	18 Years -	Assistance Publique - Hôpitaux de Paris
A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients	NCT02691975	Hormone Refract... Metastatic Pros...	SHR3680	18 Years - 80 Years	Jiangsu HengRui Medicine Co., Ltd.
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer	NCT03448458	Castration-Resi... Metastatic Pros... Stage IV Prosta...	CT (Computed To... Gallium Ga 68-D... Positron Emissi...	18 Years -	Emory University
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer	NCT05547386	Castration-Resi... Metastatic Pros... Stage IVB Prost...	Computed Tomogr... Gallium Ga 68 G... Positron Emissi...	18 Years -	Mayo Clinic
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer	NCT03821792	Metastatic Pros... Prostate Adenoc... Prostate Carcin... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Abiraterone Ace... Apalutamide Prednisone	18 Years -	M.D. Anderson Cancer Center
Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy	NCT03596710	Castration-Resi... Metastatic Pros... Stage IV Prosta...	Image Guided Bi...	-	Jonsson Comprehensive Cancer Center
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer	NCT03649841	Castration-Sens... Metastatic Mali... Metastatic Pros... Prostate Adenoc... Prostate Small ... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Antiandrogen Th... Abiraterone Ace... Prednisone Radiation Thera...	18 Years -	University of Washington
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel	NCT02491411	Hormone-Resista... Metastatic Pros... Prostate Adenoc... Stage IV Prosta...	Dexamethasone Enzalutamide Laboratory Biom... Quality-of-Life...	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer	NCT02893917	Advanced Prosta... Castration-Resi... Metastatic Pros... Metastatic Pros... Prostate Adenoc... Stage IV Prosta...	Cediranib Olaparib	18 Years -	National Cancer Institute (NCI)
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer	NCT02565901	Castration-Resi... Metastatic Pros... Stage IV Prosta... Metastatic Mali...	Carboplatin Docetaxel Laboratory Biom... Sirolimus	18 Years -	University of Washington
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression	NCT04927663	Castration-Resi... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... Solid Tumor, Ad... Solid Tumor Metastatic Cast...	Computed Tomogr... Magnetic Resona... Positron Emissi... 11C-YJH08 Optional Tumor ...	18 Years -	University of California, San Francisco
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer	NCT01377389	Prostate Cancer	Ipilimumab Leuprolide Goserelin Degarelix	18 Years -	M.D. Anderson Cancer Center
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer	NCT02565901	Castration-Resi... Metastatic Pros... Stage IV Prosta... Metastatic Mali...	Carboplatin Docetaxel Laboratory Biom... Sirolimus	18 Years -	University of Washington
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer	NCT03448458	Castration-Resi... Metastatic Pros... Stage IV Prosta...	CT (Computed To... Gallium Ga 68-D... Positron Emissi...	18 Years -	Emory University
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers	NCT04388852	Aggressive Vari... Castration-Resi... Metastatic Clea... Metastatic Mali... Metastatic Pros... Metastatic Urot... Stage IV Prosta... Stage IV Renal ... Stage IVA Prost... Stage IVB Prost...	Ipilimumab Valemetostat	18 Years -	M.D. Anderson Cancer Center
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer	NCT00748358	Prostatic Neopl... Neoplasms, Horm... Tumor Markers, ... Survival Rate Disease-Free Su...	sunitinib	18 Years -	Assistance Publique - Hôpitaux de Paris
CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer	NCT01881867	Castration Leve... Castration-Resi... Metastatic Pros... Stage IV Prosta...	Glycosylated Re... Laboratory Biom...	18 Years -	Fred Hutchinson Cancer Center
Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial	NCT06040125	PROSTATE CANCER Metastatic Pros... Metastatic Pros...	Supervised Circ...	18 Years -	Dana-Farber Cancer Institute
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	NCT04514484	Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi...	Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression	NCT02555189	Castration-Resi... Metastatic Pros... Prostate Carcin... Stage IV Prosta...	Enzalutamide Ribociclib Laboratory Biom... Pharmacological... Biospecimen Col... Biopsy Echocardiograph... Multigated Acqu... Bone Scan Computed Tomogr... Magnetic Resona...	18 Years -	Thomas Jefferson University
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	NCT01503229	Hormone-Resista... Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Abiraterone Ace... Laboratory Biom... Pharmacological... Prednisone	18 Years -	University of Washington
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer	NCT02881242	Hormone-Resista... Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Laboratory Biom... Quality-of-Life... Trametinib	18 Years -	Jonsson Comprehensive Cancer Center
Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer	NCT04279561	Castration-Resi... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Computed Tomogr... Gallium Ga 68 G... Positron Emissi...	18 Years -	Jonsson Comprehensive Cancer Center
A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients	NCT02691975	Hormone Refract... Metastatic Pros...	SHR3680	18 Years - 80 Years	Jiangsu HengRui Medicine Co., Ltd.
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	NCT03218826	Advanced Breast... Advanced Malign... Advanced Prosta... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Metastatic Brea... Metastatic Mali... Metastatic Pros... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... Triple-Negative... Unresectable So...	Docetaxel Laboratory Biom... Pharmacological... PI3Kbeta Inhibi...	18 Years -	National Cancer Institute (NCI)
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer	NCT01799278	Small Cell Pros... Neuroendocrine ... Prostate Adenoc...	MLN8237	18 Years -	Weill Medical College of Cornell University
NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer	NCT02429804	Hormone-Resista... Metastatic Mali... Metastatic Pros...	Contrast-enhanc... Fludeoxyglucose... Fluorine F 18 S... Magnetic Resona... Positron Emissi...	19 Years -	Stanford University
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	NCT02159950	Hormone-Resista... Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Laboratory Biom... Sipuleucel-T Tasquinimod	18 Years -	Roswell Park Cancer Institute
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	NCT02159950	Hormone-Resista... Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Laboratory Biom... Sipuleucel-T Tasquinimod	18 Years -	Roswell Park Cancer Institute
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects	NCT03012321	Prostate Cancer... Abnormal DNA Re... Metastatic Pros... Stage IV Prosta...	Olaparib Abiraterone Ace... Prednisone	18 Years -	Northwestern University
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer	NCT03649841	Castration-Sens... Metastatic Mali... Metastatic Pros... Prostate Adenoc... Prostate Small ... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Antiandrogen Th... Abiraterone Ace... Prednisone Radiation Thera...	18 Years -	University of Washington
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer	NCT05034562	Metastatic Pros... Recurrent Prost... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Computed Tomogr... Gallium Ga 68-l... Magnetic Resona... Positron Emissi...	18 Years -	M.D. Anderson Cancer Center
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression	NCT02555189	Castration-Resi... Metastatic Pros... Prostate Carcin... Stage IV Prosta...	Enzalutamide Ribociclib Laboratory Biom... Pharmacological... Biospecimen Col... Biopsy Echocardiograph... Multigated Acqu... Bone Scan Computed Tomogr... Magnetic Resona...	18 Years -	Thomas Jefferson University
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer	NCT02516670	Hormone-Resista... Metastatic Pros... Stage IV Prosta...	Ascorbic Acid Docetaxel Laboratory Biom... Pharmacological... Placebo Quality-of-Life...	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer	NCT02429804	Hormone-Resista... Metastatic Mali... Metastatic Pros...	Contrast-enhanc... Fludeoxyglucose... Fluorine F 18 S... Magnetic Resona... Positron Emissi...	19 Years -	Stanford University
National Cancer Institute "Cancer Moonshot Biobank"	NCT04314401	Acute Myeloid L... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Lung Non-Small ... Lung Small Cell... Malignant Solid... Metastatic Pros... Multiple Myelom... Stage III Lung ... Stage III Ovari... Stage IV Colore... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IVB Prost...	Biospecimen Col... Medical Chart R...	13 Years -	National Cancer Institute (NCI)
NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer	NCT02429804	Hormone-Resista... Metastatic Mali... Metastatic Pros...	Contrast-enhanc... Fludeoxyglucose... Fluorine F 18 S... Magnetic Resona... Positron Emissi...	19 Years -	Stanford University
Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study	NCT04447703	Biochemically R... Metastatic Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IV Prosta...	Interview Internet Based ... Survey Administ... Genetic Counsel... Genetic Testing Survey Administ... Genetic Counsel... Internet-Based ... Genetic Testing Survey Administ...	18 Years -	Thomas Jefferson University
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer	NCT04050215	Biochemically R... Metastatic Pros... Prostate Adenoc... Prostate Carcin... PSA Level Great... PSA Progression Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Computed Tomogr... Gallium Ga 68-l... Positron Emissi... Questionnaire A...	18 Years -	Jonsson Comprehensive Cancer Center
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel	NCT02491411	Hormone-Resista... Metastatic Pros... Prostate Adenoc... Stage IV Prosta...	Dexamethasone Enzalutamide Laboratory Biom... Quality-of-Life...	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation	NCT05487846	Metastatic Pros... Stage III Prost... Stage IV Prosta...	Patient Navigat... Genetic Counsel... Survey Administ... Best Practice Genetic Counsel... Survey Administ...	18 Years -	Thomas Jefferson University
Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy	NCT05869682	Advanced Prosta... Metastatic Pros... Prostate Carcin... Stage III Prost... Stage IV Prosta...	Bright White Li... Combination Dru... Electronic Heal... Quality-of-Life... Questionnaire A...	60 Years -	City of Hope Medical Center
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer	NCT03456804	Castration Leve... Castration-Resi... Metastatic Pros... PSA Progression Stage IV Prosta...	ESK981	18 Years -	Barbara Ann Karmanos Cancer Institute
Access to Genetic Testing in Underserved Patients With Cancer	NCT06422455	Breast Carcinom... Male Breast Car... Malignant Solid... Metastatic Pros... Ovarian Carcino... Pancreatic Exoc... Stage IVB Prost... Triple-Negative...	Best Practice Educational Int... Electronic Heal... Genetic Counsel... Interview Survey Administ...	18 Years -	University of Southern California
National Cancer Institute "Cancer Moonshot Biobank"	NCT04314401	Acute Myeloid L... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Lung Non-Small ... Lung Small Cell... Malignant Solid... Metastatic Pros... Multiple Myelom... Stage III Lung ... Stage III Ovari... Stage IV Colore... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IVB Prost...	Biospecimen Col... Medical Chart R...	13 Years -	National Cancer Institute (NCI)
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer	NCT02807805	Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Abiraterone Ace... Niclosamide Prednisone	19 Years -	University of California, Davis
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies	NCT03217747	Advanced Malign... Castration-Resi... Malignant Solid... Metastatic Mali... Metastatic Pros... Prostate Carcin... Refractory Mali... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Avelumab Ivuxolimab Radiation Thera... Utomilumab	18 Years -	M.D. Anderson Cancer Center
Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial	NCT06040125	PROSTATE CANCER Metastatic Pros... Metastatic Pros...	Supervised Circ...	18 Years -	Dana-Farber Cancer Institute
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial	NCT06244004	Castration-Sens... Metastatic Pros... Stage IVB Prost...	Antiandrogen Th... Bone Scan Computed Tomogr... Cytotoxic Chemo... FDG-Positron Em... Radiation Thera...	18 Years -	Northwestern University
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies	NCT02985021	Hormone-Resista... Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Carboplatin Docetaxel	18 Years -	Seattle Institute for Biomedical and Clinical Research
68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy	NCT04928820	Biochemically R... Metastatic Mali... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Computed Tomogr... Gallium Ga 68 G... Positron Emissi...	18 Years -	Jonsson Comprehensive Cancer Center
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer	NCT06305598	Castration-Resi... Metastatic Pros... Stage IVB Prost...	Biopsy Bone Scan Computed Tomogr... Leuprolide Acet... Magnetic Resona... Survey Administ... Testosterone Cy...	18 Years -	Roswell Park Cancer Institute
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial	NCT06244004	Castration-Sens... Metastatic Pros... Stage IVB Prost...	Antiandrogen Th... Bone Scan Computed Tomogr... Cytotoxic Chemo... FDG-Positron Em... Radiation Thera...	18 Years -	Northwestern University
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer	NCT02881242	Hormone-Resista... Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Laboratory Biom... Quality-of-Life... Trametinib	18 Years -	Jonsson Comprehensive Cancer Center
Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients	NCT02853097	Hormone-Resista... Metastatic Pros... Prostate Adenoc...	Cytology Specim... Laboratory Biom...	18 Years -	University of Southern California
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)	NCT05241860	Castration-Sens... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Pharmacotherapy... Follow-Up Questionnaire A... Quality-of-Life...	18 Years -	Alliance for Clinical Trials in Oncology
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy	NCT04071236	Castration-Resi... Metastatic Mali... Metastatic Pros... Stage IV Prosta...	Avelumab Biospecimen Col... Bone Scan Computed Tomogr... Magnetic Resona... Peposertib Questionnaire A... Radium Ra 223 D...	18 Years -	National Cancer Institute (NCI)
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy	NCT01953640	Hormone-Resista... Metastatic Pros... Prostate Adenoc... Recurrent Prost...	Laboratory Biom... Quality-of-Life...	18 Years -	Mayo Clinic
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer	NCT03821792	Metastatic Pros... Prostate Adenoc... Prostate Carcin... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Abiraterone Ace... Apalutamide Prednisone	18 Years -	M.D. Anderson Cancer Center
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer	NCT02565901	Castration-Resi... Metastatic Pros... Stage IV Prosta... Metastatic Mali...	Carboplatin Docetaxel Laboratory Biom... Sirolimus	18 Years -	University of Washington
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial	NCT06244004	Castration-Sens... Metastatic Pros... Stage IVB Prost...	Antiandrogen Th... Bone Scan Computed Tomogr... Cytotoxic Chemo... FDG-Positron Em... Radiation Thera...	18 Years -	Northwestern University
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer	NCT05034562	Metastatic Pros... Recurrent Prost... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Computed Tomogr... Gallium Ga 68-l... Magnetic Resona... Positron Emissi...	18 Years -	M.D. Anderson Cancer Center
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer	NCT04716725	Castration-Resi... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	68Ga-PSMA-11 Positron Emissi...	18 Years -	University of California, San Francisco
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer	NCT03751436	Castration Leve... Castration-Resi... Metastatic Pros... Metastatic Pros... Prostate Carcin... PSA Progression Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Enzalutamide Venetoclax	18 Years -	Roswell Park Cancer Institute
Access to Genetic Testing in Underserved Patients With Cancer	NCT06422455	Breast Carcinom... Male Breast Car... Malignant Solid... Metastatic Pros... Ovarian Carcino... Pancreatic Exoc... Stage IVB Prost... Triple-Negative...	Best Practice Educational Int... Electronic Heal... Genetic Counsel... Interview Survey Administ...	18 Years -	University of Southern California
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study	NCT04585932	Biochemically R... Metastatic Pros... Oligometastatic... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Apalutamide Degarelix Leuprolide Acet... Quality-of-Life... Questionnaire A... Radiation Thera...	18 Years -	M.D. Anderson Cancer Center
Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study	NCT04447703	Biochemically R... Metastatic Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IV Prosta...	Interview Internet Based ... Survey Administ... Genetic Counsel... Genetic Testing Survey Administ... Genetic Counsel... Internet-Based ... Genetic Testing Survey Administ...	18 Years -	Thomas Jefferson University
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer	NCT04716725	Castration-Resi... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	68Ga-PSMA-11 Positron Emissi...	18 Years -	University of California, San Francisco
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression	NCT02555189	Castration-Resi... Metastatic Pros... Prostate Carcin... Stage IV Prosta...	Enzalutamide Ribociclib Laboratory Biom... Pharmacological... Biospecimen Col... Biopsy Echocardiograph... Multigated Acqu... Bone Scan Computed Tomogr... Magnetic Resona...	18 Years -	Thomas Jefferson University
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging	NCT04423211	Biochemically R... Metastatic Pros... Prostate Adenoc... Stage IVB Prost...	3-Dimensional C... Apalutamide Computed Tomogr... Degarelix External Beam R... Fluciclovine F1... Goserelin Aceta... Intensity-Modul... Intensity-Modul... Leuprolide Acet... Magnetic Resona... Positron Emissi... Quality-of-Life... Questionnaire A... Relugolix Stereotactic Bo... Triptorelin Volume Modulate...	18 Years -	Eastern Cooperative Oncology Group
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer	NCT04050215	Biochemically R... Metastatic Pros... Prostate Adenoc... Prostate Carcin... PSA Level Great... PSA Progression Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Computed Tomogr... Gallium Ga 68-l... Positron Emissi... Questionnaire A...	18 Years -	Jonsson Comprehensive Cancer Center
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy	NCT01953640	Hormone-Resista... Metastatic Pros... Prostate Adenoc... Recurrent Prost...	Laboratory Biom... Quality-of-Life...	18 Years -	Mayo Clinic
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy	NCT01953640	Hormone-Resista... Metastatic Pros... Prostate Adenoc... Recurrent Prost...	Laboratory Biom... Quality-of-Life...	18 Years -	Mayo Clinic
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer	NCT02935205	Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Enzalutamide Indomethacin	19 Years -	University of California, Davis
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer	NCT05547386	Castration-Resi... Metastatic Pros... Stage IVB Prost...	Computed Tomogr... Gallium Ga 68 G... Positron Emissi...	18 Years -	Mayo Clinic
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer	NCT02499835	Hormone-Resista... Metastatic Mali... Metastatic Mali... Metastatic Pros... Prostate Adenoc... Recurrent Prost... Stage IV Prosta...	Pembrolizumab pTVG-HP Plasmid...	18 Years -	University of Wisconsin, Madison
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer	NCT01377389	Prostate Cancer	Ipilimumab Leuprolide Goserelin Degarelix	18 Years -	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: